Scholarlink

Purpose <p>Somatostatin analogues (SSAs) have been demonstrated to aid hormonal control and reduce tumour size in patients with growth hormone (GH)-secreting macroadenomas. These tumours have varying genetic profiles and do not all respond to SSA therapy. Patients with variants in the aryl-hydrocarbon-receptor interactive protein gene (<i>AIP</i>) often have young-onset invasive tumours with poor SSA response. We sought to assess whether protein expression of AIP could be correlated to lanreotide response and imaging characteristics.</p> Methods <p>Eligible patients recruited to a trial of lanreotide therapy (120&#xa0;mg Lanreotide Autogel<sup>®</sup> monthly for 12 months) had their hormone profile (GH, IGF-1) and pituitary MRI monitored at 3, 6 and 12 months. Surgery was planned after 12 months, or earlier if deemed necessary. Immunohistochemical AIP-staining was performed and an AIP-staining score calculated based on AIP expression across 10 random areas.</p> Results <p>20 patients were recruited: 16 had AIP-staining following surgery, 19 full hormone profiles. A reduction of IGF-1 at 12 months was observed in 10 patients (mean 1.09 x upper limit of normal), whilst 6 patients were considered “not biochemically controlled (at 12 months)” (mean 2.51 x upper limit of normal) and 3 required early surgery. A significant correlation between AIP-staining score and %-reduction in IGF-1 was seen. The mean tumour shrinkage over 12 months (25%) was non-significantly greater in patients with high versus low AIP-staining.</p> Conclusion <p>Higher expression of AIP after pre-operative SSA treatment was correlated with better hormone response to lanreotide. Future exploration of AIP expression in matched SSA-treated and non-treated patients would aid understanding of mechanisms involved.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

AIP expression and imaging findings in somatotroph adenomas after pre-operative lanreotide therapy for acromegaly

  • 期刊论文

  • 发表日期：

    2026年3月25日

查看全文
  • Ellie Edlmann,
  • Muhammad Shahzad,
  • Jason Yuen,
  • Samiul Muquit,
  • Aditya Shivane,
  • Márta Korbonits,
  • Daniel Flanagan

摘要

Purpose

Somatostatin analogues (SSAs) have been demonstrated to aid hormonal control and reduce tumour size in patients with growth hormone (GH)-secreting macroadenomas. These tumours have varying genetic profiles and do not all respond to SSA therapy. Patients with variants in the aryl-hydrocarbon-receptor interactive protein gene (AIP) often have young-onset invasive tumours with poor SSA response. We sought to assess whether protein expression of AIP could be correlated to lanreotide response and imaging characteristics.

Methods

Eligible patients recruited to a trial of lanreotide therapy (120 mg Lanreotide Autogel® monthly for 12 months) had their hormone profile (GH, IGF-1) and pituitary MRI monitored at 3, 6 and 12 months. Surgery was planned after 12 months, or earlier if deemed necessary. Immunohistochemical AIP-staining was performed and an AIP-staining score calculated based on AIP expression across 10 random areas.

Results

20 patients were recruited: 16 had AIP-staining following surgery, 19 full hormone profiles. A reduction of IGF-1 at 12 months was observed in 10 patients (mean 1.09 x upper limit of normal), whilst 6 patients were considered “not biochemically controlled (at 12 months)” (mean 2.51 x upper limit of normal) and 3 required early surgery. A significant correlation between AIP-staining score and %-reduction in IGF-1 was seen. The mean tumour shrinkage over 12 months (25%) was non-significantly greater in patients with high versus low AIP-staining.

Conclusion

Higher expression of AIP after pre-operative SSA treatment was correlated with better hormone response to lanreotide. Future exploration of AIP expression in matched SSA-treated and non-treated patients would aid understanding of mechanisms involved.